Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyperpolarized 129Xe MR Imaging of Lung Function
NCT04624490Phase 1Recruiting
- Start
- Nov 2020
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hyperpolarized xenon gas in asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD) and 3 more. Primary endpoint: Red Blood Cell to Barrier Ratio at Day 1. Started Nov 2020; status: recruiting.
02
Drugs
hyperpolarized xenon gas
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)interstitial lung disease (ILD)cystic fibrosis (CF)pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT04624490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624490.